Chronic kidney disease Glucose Insulin resistance Hepcidin Iron a b s t r a c t Background: Chronic kidney failure is associated with many kinds of metabolic changes caused by the kidney disease itself and by dialysis treatment. Chronic kidney disease (CKD) and hemodialysis patients (HD) are associated with increased serum hepcidin levels, the main regulator of iron metabolism and modulated in response to anemia, hypoxia, or inflammation.
Introduction
Chronic kidney disease is a very real and growing problem. The total number of treated patients has markedly increased during the last 30 years (Snyder and Pendergraph, 2005) . The cause of this may be explained by the growing percentage of elderly people in the population as well as by technical progress and broader availability of dialysis therapy also the increasing number of diabetic patients may be a further important factor (Van Biesen et al., 2006) . Many kinds of metabolic changes may accompany chronic kidney failure either caused by the kidney disease itself or due to dialysis treatment. The accumulation or deficit of various substances and dysregulation of metabolic pathways may participate and combine in the pathogenesis of these changes. Chronic kidney failure may cause deficit of some important substances that may be caused by increased losses during dialysis sessions, deficient intake in the diet, impaired intestinal absorption, or disturbed synthesis of some essential metabolic regulators such as erythropoietin or active vitamin D in kidneys (Cibulka and Racek, 2007) .
Metabolic complications of chronic kidney failure and hemodialysis include changes in acid-base balance and changes in metabolism of proteins, carbohydrates and lipids. Additionally, chronic kidney disease is complicated by renal anemia, bone mineral disease, atherosclerosis and cardiovascular disease and oxidative stress (Cibulka and Racek, 2011) . Hepcidin is a small defensin-like peptide produced primarily by hepatocytes, also by other cells like macrophages. Hepcidin has antimicrobial properties and it is the main regulator of iron metabolism that controls both the amount of dietary iron absorbed in the duodenum and the iron release by reticuloendothelial cells (Tsuchiya and Nitta, 2013) . The expression of hepcidin is upregulated by a variety of stimuli such as inflammation and iron overload, and downregulated by hypoxia, anemia, and iron deficiency. CKD is associated with increased serum hepcidin levels that may contribute to the development and severity of anemia and to resistance to erythropoiesis-stimulating agents. Elevated serum hepcidin levels contribute to the dysregulation of iron homeostasis in CKD patients (Tsuchiya and Nitta, 2013) . Treatment with agents that lower serum hepcidin levels or inhibit its actions may be an effective approach for restoring normal iron homeostasis and improving anemia in CKD patients. The aim of this article was to investigate first, the correlation of hepcidin levels with the glycemic status, lipid profile, inflammatory status, and iron status in patients with CKD on conservative treatment and in hemodialysed patients. Second, the predictors of hepcidin level in these patients.
2.
Subjects and methods
Subjects
The study included thirty healthy controls, 40 consecutive patients with CKD who visited the outpatient Nephrology clinic of different hospitals in Taif, KSA, to ensure coverage of the full GFR range and 54 consecutive patients on hemodialysis, using a biocompatible Fresenius Polysulfone R dialysis membrane. These patients did not receive intravenous iron or erythropoietin (EPO) during dialysis. Relevant clinical and biochemical data were retrieved from the patients' records. Inclusion criteria for the maintenance hemodialysis patients were the initiation of maintenance hemodialysis ! 6 months (three times per week for 4e5 h per session) prior the study and a baseline hemoglobin (Hb) level > 10 g/dl.
Exclusion criteria were the previous treatment with immunosuppressive drugs, active inflammatory disease, clinical signs of acute infection, liver disease, any malignancy, evidence of blood loss gastrointestinal bleeding, trauma, etc. Healthy controls had to have no clinical or laboratory evidence of any chronic disease. The study was approved by all participants gave informed consent and the study followed the rules of the National Medical Committee for Medical and Bioethics. Thorough clinical examination including waist circumference height, weight, BMI is also calculated as weight in kg/(height in meters) 2 . Blood pressure measurement was done using manual sphygmomanometer. Mean arterial blood pressure (MAP) was also calculated. MAP ¼ [(2 Â diastolic) þ systolic]/3.
Sampling
In hemodialysis patients, blood samples were collected at the start of hemodialysis. Peripheral blood samples were collected midweek from maintenance hemodialysis patients, after an overnight fast, immediately before and after a single session of hemodialysis. The samples were put into pyrogen-free tubes containing clot activator (without anticoagulant). After coagulation, samples were centrifuged (at 1500 Â g for 15 min) and serum was harvested, aliquoted and stored at À70 C until analysis. For healthy control subjects, and chronic kidney disease, blood was also drawn from a peripheral vein after an overnight fast.
Methods
Serum hepcidin levels were measured using the commercially available human hepcidin C-ELISA kit (Cusabio Biotech, Wuhan, China) according to the manufacturer's instructions. Fasting blood sugar (FBS), Total cholesterol (TC), triglycerides (TG), hemoglobin (Hb), hematocrit (Ht), total protein, albumin, fibrinogen, highly specific C-reactive protein (hsCRP) creatinine, blood urea, iron, ferritin, total iron-binding capacity (TIBC) were assayed using Synchron CX-9 (Instruments Inc.; Scientific Instruments Division, Fullerton, CA 92634, 3100, USA.) system auto analyzer applying enzymatic colorimetric method (interassay CVs < 3%). Insulin was assayed by Microparticle Enzyme Immunoassay (MEIA) on the AxSYM (Abbott Ireland, Diagnostic Division-Lisnamuck, Longford Co., Longford, Ireland þ353-43-31000) for the quantitative determination of insulin in human serum or plasma. The homeostasis model assessment-insulin resistance index (HOMA-IR): It was calculated using the equation: HOMA-IR ¼ fasting glucose (mg/DL) Â fasting insulin (mU/ml) ÷ 405. The cutoff point to define insulin resistance corresponds to HOMA-IR ! 3.8 (Shirai, 2004) . The glomerular filtration rate was estimated (eGFR) by the simplified Modification of Diet in Renal Disease formula (Levey et al., 1999) . Wakeel et al., 2009 ).
Statistical analysis
Data are expressed as the mean ± SD. Each variable was assessed for a normal distribution. Using the Kolmogor-oveSmirnov test. Statistical differences between the groups were identified using one-way analysis of variance (ANOVA) followed by post-test. Pearson's correlation test was performed to determine the relationships between serum hepcidin levels and study variables. Multiple linear step-wise regression analysis with hepcidin as a dependent variable was performed to identify the risk factors which determined its level. All statistical results were based on two-sided tests.
Data were analyzed using Package for Social Sciences (SPSS) software for Windows (version 12.0; SPSS Inc., Chicago, IL, USA). p < .05 was regarded as significant.
Results
There was an insignificant (p > .05) difference in age between the study groups while, BMI was significantly (p < .05) higher in patients with CKD compared to control and HD groups.
Glycemic status
Both CKD and HD patients had significantly (p < .001) higher, fasting blood sugar, fasting serum insulin, HOMA-IR when compared to normal subjects. All these parameters were significantly higher in HD patients than in CKD patients (p < .05, p < .01, p < .05 respectively).
Lipid profile
Cholesterol and triglycerides were significantly (p < .001) higher in both patient groups compared to normal group. Moreover, triglycerides was significantly (p < .01) higher in HD patients than that of CKD patients.
Inflammatory markers
Fibrinogen and hsCRP are significantly higher in CKD (p < .001, p < .01 respectively) and HD (p < .001, p < .001 respectively) patients compared to control subjects. Moreover, these two parameters were significantly (p < .05, p < .01 respectively) higher in HD patients compared to CKD patients. Total protein and albumin were significantly lower in both patient groups compared to normal group with no significant difference was found between the two patient groups.
Renal function
Both CKD and HD patients had significantly higher (p < .001) creatinine and urea when compared to control subjects, with significantly higher (p < .01) result in HD patients compared to CKD patients. HD patients had significantly lower (p < .01) eGFR compared to CKD patients. Moreover, both patient groups had significantly lower (p < .001) eGFR than that of normal group.
Hepcidin and iron status
Hepcidin (Fig. 1 ) and ferritin (Table 1 ) are significantly higher (p < .001) in CKD patients and in HD patients compared to control subjects with being significantly higher in HD patients compared to CKD patients. Hb, iron and TIBC were significantly lower (p < .001) in CKD patients and HD patients compared to control subjects. Also, Ht was significantly lower (p < .01) in CKD patients and HD patients than that of control subjects. Iron was significantly higher (p < .01) in HD patients than in CKD patients but TIBC and Ht were significantly lower in HD patients than in CKD patients with no significant difference was found between the two patient groups regarding Hb level (Table 1) .
Correlation study
The association between studied variables had been tested by Pearson's correlation coefficient with p-values < .05 was considered as statistically significant (Table 2 ). In CKD and HD patients, hepcidin was associated with the glycemic status parameters, also with total protein, creatinine and ferritin. In CKD patients only, hepcidin was correlated to cholesterol and Fig. 1 e Serum hepcidin level in different groups, it was significantly higher (p < .001) in CKD and HD groups compared to control groups. HD patients had a significantly higher (p < .01) hepcidin than CKD patients.
albumin. However, in HD patients hepcidin was correlated with GFR, Hb and TIBC.
Stepwise regression analysis
Stepwise regression analysis of CKD patients showed that the best predictors for hepcidin levels in this group were serum albumin, cholesterol and HOMA-IR as they account for 83.9% of the variance in the level of hepcidin in this group (Table 3) (F ¼ 68.69, p ¼ .000). Moreover, regression analysis of HD patients showed that the best predictors for hepcidin levels in this group were serum ferritin, FBS and creatinine as they account for 58.1% of the variance in the level of hepcidin in this group (Table 4 ) (F ¼ 25.527, p ¼ .000).
Discussion
In both patient groups, hepcidin was correlated to fasting blood sugar, fasting plasma insulin, HOMA-IR, total protein, creatinine, ferritin. But it was correlated to cholesterol and albumin in CKD patients only and to GFR, Hb and TIBC in HD group not in CKD patients. Moreover, regression analysis in these patients showed that the best predictors for hepcidin levels in this group were serum ferritin, FBS and creatinine as they account for 58.1% of the variance in the level of hepcidin in this group. Stepwise regression analysis in CKD patients showed that the best predictors for hepcidin levels in this group were serum albumin, cholesterol and HOMA-IR as they account for 83.9% of the variance in the level of hepcidin in this group. Abnormalities of carbohydrate metabolism are very common in patients with chronic kidney failure. Impaired glucose tolerance occurs together with the loss of kidney function (Alvestrand, 1997) . Insulin resistance is primarily obvious when GFR is below 50 ml/min. Reduced insulin-mediated non-oxidative glucose disposal is the most marked defect of glucose metabolism, but impairments of glucose oxidation, the defective suppression of endogenous glucose production, and abnormal insulin secretion also contribute to uremic glucose intolerance. Accumulation of nitrogenous uremic toxins appears to be the leading cause of a specific defect in insulin action. The consequences of chronic kidney failure, such as exercise intolerance, metabolic acidosis, anemia, secondary hyperparathyroidism, or inadequate activation of vitamin D also indirectly play a role .01 level (2-tailed) .
b e n i -s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 3 ( 2 0 1 4 ) 1 3 3 e1 3 9 (Rasic-Milutinovic et al., 2000) . Aigner et al. (2013) reported an additional aspect of the insulin/glucose-like regulation of serum iron concentrations, namely, hepcidin, in response to glucose. Furthermore, cell culture experiments suggest that the pancreatic b-cell may serve as the common source of both insulin and hepcidin after glucose absorption from the gut. These findings suggest that glucose, likely by triggering the release of hepcidin from pancreatic b-cells, may represent a novel regulator of serum iron concentrations. Hepcidin and ferritin are significantly higher in chronic kidney disease patients and in hemodialysed patients compared to control subjects. Also, Malyszko et al. found that in their study on patients with chronic renal failure and hemodialyzed patients, serum, ferritin and hepcidin were significantly higher than in the healthy volunteers. Our study agrees with the study of Peters et al., on hemodialysis patients who exhibited significantly higher hepcidin-25 levels than patients with CKD. Peters et al., revealed that, serum hepcidin-25 levels decreased only slightly during hemodialysis (10e15%), this may be explained as ultrafiltration may have resulted in more concentrated levels of hepcidin-25 and a minor underestimation of hepcidin clearance. Our data also agree with some studies reporting higher hepcidin levels in HD patients (Ashby et al., 2009; Tomosugi et al., 2006) . However, our present data disagree with the results of Pelusi et al., who revealed that serum hepcidin-25 levels were not significantly different between the whole group of chronic hemodialysis patients (CHD) patients and controls. The failure to confirm a relative hyper-hepcidinemia in the overall CHD group could be explained by a number of reasons such as, the inclusion of a large and less selected CHD population compared to previous studies, including those requiring high doses of Epo and with relative iron deficiency (factors both known to reduce hepcidin), also, the relatively low average iron stores in this cohort as reflected by median serum ferritin levels of only 265 ng/ml (Pelusi et al., 2013) . The elevated levels serum hepcidin in patients with renal failure, may reflect an underlying inflammatory state associated with advanced renal failure, loss of kidney function, and development of anemia of chronic disease, the thing that was obvious in the present study in the form of high fibrinogen and hsCRP in chronic kidney disease patients and hemodialysed patients but we could not find a significant correlation between hepcidin and either fibrinogen or hsCRP. CKD is associated with a chronic imbalance of prooxidant and antioxidant factors that results in a state of chronic inflammation. Oxidative stress induces both insulin resistance by decreasing internalization of insulin (Bertelsen et al., 2001) and increased ferritin synthesis. Free radicals originate from leucocytes, which are activated during the contact with the dialysis membrane, and also from erythrocyte iron released as a consequence of hemolysis (Eiselt et al., 1999) . Ferritin is the cellular storage protein for iron and it is an acute phase reactant, that orchestrates the cellular defense against stress and inflammation (Torti, and Torti, 2002) . In some patients with chronic renal failure, on conservative treatment and on dialyses, functional iron deficiency is present which is characterized by the presence of adequate iron stores with serum ferritin level is either normal or elevated. In addition, inflammatory iron block occurs among these patients due largely to an underlying inflammatory state and both functional deficiency and inflammatory block cause elevated ferritin level (Malyszko et al., 2006) . Hepcidin in the present study in the two groups of patients, was related to ferritin that agrees with the results of Peters et al., who revealed that serum ferritin concentration was a significant predictor of hepcidin-25 levels in multiple regression analysis. However, Malyszko et al., could not find significant correlations between hepcidin and ferritin in patients with chronic renal failure on conservative treatment and on hemodialyses. In addition, Kulaksiz et al. (2004) , described no correlation between hepcidin and ferritin was observed in their study on hemodialyses patients. However, Peters et al., revealed that serum ferritin concentration was a significant predictor of hepcidin-25 levels in multiple regression analysis. Similar correlation between ferritin and hepcidin was reported by Dallalio et al., in anemic patients undergoing diagnostic bone marrow examination. In our study we observed that in the two groups of patients hepcidin, was related to total protein and creatinine but not correlated with iron. Our results agree with the results of Malyszko et al., who revealed that in patients with chronic renal failure, hepcidin was correlated significantly in univariate analysis, with total protein, and creatinine but not with iron. Taes et al. (2004) , reported that hepcidin accumulates in renal insufficiency on the basis of hepcidin correlations with Cr-EDTA clearance rate, creatinine clearance rate, and serum creatinine. Kulaksiz et al., suggested that kidneys, besides the liver, may participate in the hepcidin elimination as well. They reported that hepcidin was produced as an intrinsic peptide in the epithelial cells of the tubule and collecting duct in mammalian kidney and might be released luminally into the urine (Dallalio et al., 2003) . Our present data revealed that creatinine was in correlate to hepcidin partly support this hypothesis. The present study revealed that hepcidin, was related to albumin in the CKD patients but not in hemodialysis patients which was consistent with the results of Malyszko et al., who revealed that in patients with chronic renal failure, hepcidin correlated significantly in univariate analysis, with albumin. Hepcidin in the present study, was related to GFR in hemodialysis but not in the CKD patients. These findings disagree with the studies of Kuan et al. (2005) , and Dallalio et al., where, the independent effect of eGFR on hepcidin levels was not evaluated in their study but agrees with the results of Ashby et al., who reported that hepcidin levels in their patients were significantly correlated with eGFR. Peters et al., also could not find a correlation between hepcidin-25 and eGFR. The authors explained this finding by the hypotheses that hepcidin-25 differs from other LMW proteins such as b 2 -microglobulin or cystatin-C. They postulated that hepcidin bind to a large carrier protein that prevent it to be freely filtered. Nevertheless, their additional studies were inconsistent with such a hypothesis. Primarily, the estimated hepcidin clearance was compatible with the expected clearance of a freely filterable protein of similar molecular mass. Secondarily, the arterio-venous difference in hemodialysis patients suggests that hepcidin-25 is handled similar to other LMW proteins. However, they were unable to estimate the relative role of ultrafiltration and of sticking to the membrane of the artificial kidney. In view of the fact that blood samples were not taken until after the start of hemodialysis, it is difficult to exclude an immediate effect of hemodialysis on serum hepcidin levels, so far, it seems improbably that hepcidin levels are significantly affected by hemodialysis in this little period of time (Peters et al., 2009 ). In conclusion, in CKD and HD patients, hepcidin was associated with the glycemic status parameters, also with total protein, creatinine and ferritin. Hepcidin was correlated to cholesterol and albumin only in CKD patients. However, hepcidin was correlated with GFR, Hb and TIBC in HD patients but they were not considered as independent predictors for hepcidin level in these patients. Serum albumin, cholesterol and HOMA-IR are the best predictors for hepcidin levels in CKD patients as they account for 83.9% of the variance in hepcidin level in this group. Moreover, in HD patients the best predictors for hepcidin levels in this group were serum ferritin, FBS and creatinine as they account for 58.1% of the variance in the level of hepcidin in this group. So if we can control the glycemic status in these patients we can adjust the level of hepcidin and if we can decrease the level of hepcidin we can control the anemia in the chronic diseases. r e f e r e n c e s
